News

Patient Perspectives: Understanding Telemedicine

With telemedicine trending to be a mainstay in how healthcare professionals treat patients, Ameet Doshi, MD, MBA, Lead Hospitalist for Telemedicine at HealthPartners, shares what is contributing to the surge and how it affects lymphoma patients and survivors.

U.S. Food and Drug Administration Approves Lisocabtagene Maraleucel (liso-cel, BREYANZI) for Large B-cell Lymphoma

Lisocabtagene maraleucel (BREYANZI) is the fourth chimeric antigen receptor (CAR) T cell therapy approved for certain types of non-Hodgkin lymphoma (NHL).

U.S. Food and Drug Administration Approves Umbralisib (UKONIQ) for Marginal Zone Lymphoma and Follicular Lymphoma

Umbralisib (UKONIQ, TG Therapeutics), a kinase inhibitor including PI3K-delta and casein kinase CK1-epsilon, has been approved for relapsed or refractory marginal zone lymphoma and follicular lymphoma.

LRF Publishes Proceedings of the Inaugural International Marginal Zone Lymphoma Scientific Workshop

The white paper provides a summary of the workshop proceedings, presents the key findings of each speaker, and highlights the unmet needs identified during the post-workshop discussion with suggested immediate and long-term solutions.

LRF Urges CDC to Prioritize Blood Cancer Patients for COVID-19 Vaccine

LRF Urges CDC to Prioritize Blood Cancer Patients for COVID-19 Vaccine VISIT THE COVID-19 LEARNING CENTER FOR…

Ask the Doctor: Should CLL patients receive the COVID vaccine while they are on treatment with BTK inhibitors considering that they have to stay on them indefinitely?

Ask the Doctor: Should CLL patients receive the COVID vaccine while they are on treatment…

Ask the Doctor: Does CHOP chemotherapy remain the go-to frontline treatment for peripheral T-cell lymphoma or have new therapies been added in combination to this regimen?

Peripheral T-cell lymphoma (PTCL) is an aggressive (fast-growing) form of non-Hodgkin lymphoma which has typically…